MYELODYSPLASTIC SYNDROME: CLASSIFICATION, PROGNOSIS, TREATMENT
https://doi.org/10.51523/2708-6011.2013-10-3-11
Abstract
The use of the modern classification of myelodysplastic syndrome makes it possible to standardize the approaches to diagnosis and treatment of patients with this pathology. An approach to MDS treatment should be individualized and based on the definition of risk groups, age and somatic status. Among treatment strategies, epigenetic therapy with decitabine is given advantage in terms of quality of life. The decitabine therapy is clinically effective, demonstrating a high level of response to therapy in patients with myelodysplastic syndrome.
About the Authors
A. L. Uss
Republican Center for Hematology and Bone Marrow Transplantation at Public Health Institution «Municipal Clinical Hospital No.9», Minsk
Belarus
Belarus
I. A. Iskrov
Republican Center for Hematology and Bone Marrow Transplantation at Public Health Institution «Municipal Clinical Hospital No.9», Minsk
Belarus
Belarus
V. V. Smolnikova
Republican Center for Hematology and Bone Marrow Transplantation at Public Health Institution «Municipal Clinical Hospital No.9», Minsk
Belarus
Belarus
M. I. Mogilevtsev
Republican Center for Hematology and Bone Marrow Transplantation at Public Health Institution «Municipal Clinical Hospital No.9», Minsk
Belarus
Belarus
References
1. Santini, V. Changes in DNA methylation in neoplasia: Pathophysiology and therapeutic implications / V. Santini, H. M. Kantarjian, J. P. Issa // Ann Intern Med. - 2001. - Vol. 134. - P. 573-586.
2. National Comprehensive Cancer Network: Clinical Practice Guidelines in Oncology: Myelodysplastic Syndromes, 2006. - Vol. 4: National Comprehensive Cancer Network, 2006. http://www.nccn.org.
3. The myelodysplastic syndromes / R. Hoffman [et al.] // Hematology: Basic Principles and Practice. (ed 3rd.): New York: Churchill Livingstone, 2000. - P. 1106-1129.
4. A decision analysis of allogeneic bone marrow transplantation for the myelodysplastic syndromes: delayed transplantation for low-risk myelodysplasia is associated with improved outcome / C. S. Cutler [et al.] // Blood. - 2004. - Vol. 104. - P. 579-585.
5. Pinto, A. 5-Aza-2¢-deoxycytidine (Decitabine) and 5-azacytidine in the treatment of acute myeloid leukemias and myelodysplastic syndromes: Past, present and future trends / A. Pinto, V. Zagonel, H. Leukemia. - 1993. - Vol. 7, (suppl 1). - P. 51-60.
6. Van den Bosch, J. The effects of 5-aza-2'-deoxycytidine (decitabine) on the platelet count in patients with intermediate and high-risk myelodysplastic syndromes. Leuk Res / J. Van den Bosch, M. Lubbert, G. Verhoef. - 2004. - Vol. 28. - P. 785-790.
7. Decitabine improves patient outcomes in myelodysplastic syndromes: results of a phase III randomized study / H. Kantarjian [et al.] // Cancer. - 2006. - Vol. 106. - P. 1794-1803.
8. Results of a randomized study of 3 schedules of low-dose decitabine in higher-risk myelodysplastic syndrome and chronic myelomonocytic leukemia / H. Kantarjian [et al.] // Blood. - 2007. - Vol. 109. - P. 52-57.
Review
For citations:
Uss A.L., Iskrov I.A., Smolnikova V.V., Mogilevtsev M.I. MYELODYSPLASTIC SYNDROME: CLASSIFICATION, PROGNOSIS, TREATMENT. Health and Ecology Issues. 2013;(3):57-62. (In Russ.) https://doi.org/10.51523/2708-6011.2013-10-3-11
Views: 293
Email this article 